Abstract
The U.S. Food and Drug Administration approved the use of trametinib and dabrafenib in combination for patients with metastatic or unresectable melanoma with BRAF V600K or V600E mutations-the first combination therapy approved for the disease.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Humans
-
Imidazoles / administration & dosage
-
Melanoma / drug therapy*
-
Melanoma / genetics
-
Molecular Targeted Therapy
-
Oximes / administration & dosage
-
Proto-Oncogene Proteins B-raf / genetics*
-
Proto-Oncogene Proteins B-raf / metabolism
-
Pyridones / administration & dosage
-
Pyrimidinones / administration & dosage
-
Treatment Outcome
-
United States
-
United States Food and Drug Administration
Substances
-
Antineoplastic Agents
-
Imidazoles
-
Oximes
-
Pyridones
-
Pyrimidinones
-
trametinib
-
Proto-Oncogene Proteins B-raf
-
dabrafenib